Medco, MolecularMD team on CML test

Medco Health Solutions and MolecularMD have launched a personalized medicine program for chronic myeloid leukemia (CML) patients.  Medco will offer patients diagnosed with CML a molecular test known as quantitative real-time polymerase chain reaction (qRT-PCR) BCR-ABL to monitor the disease. Documenting BCR-ABL levels prior to initiation of therapy and then monitoring levels during treatment allows patients and their doctors to determine how well the medicine is working and make adjustments as needed. The test will be offered as part of the DNA Direct by Medco clinical testing program services. Medco/MolecularMD release

Suggested Articles

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.